Edwards Lifesciences Corporation announced that Health Canada has approved its INSPIRIS RESILIA aortic valve, the first in a new class of resilient heart valves. The device is now commercially available. The INSPIRIS valve features three differentiating elements: RESILIA tissue, a breakthrough tissue technology that delivers the combination of enhanced anti-calcification properties, improved sustained hemodynamic performance and dry storage; A first-of-its-kind expandable frame, VFit technology also incorporates fluoroscopically visible size markers and is designed for potential future valve-in-valve procedures; A trusted valve platform built on the proven performance of the Carpentier-Edwards PERIMOUNT valve design, which has more than 20 years of published clinical durability.